The importance of antibody drug conjugates research is unquestionable and researchers are now aware of their great potential in cancer treatment. Oxford Global's free webinar recording offers attendees a unique chance to hear our host speak on next generation antibody drug conjugates and their potential as magic anti-cancer bullets.'Next Generation of Antibody Drug Conjugates: A Step Forward to Magic Anti-cancer Bullets'
Hosted by Rakesh Dixit, Vice President, Research & Development, MedImmune. Rakesh's areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity. Rakesh is the Editor-in-chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. He was selected by his pharmaceutical peers as the 100 Most Inspiring People in Pharmaceutical Industry by PharmaVOICE in 2015. And also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.
Download this webinar recording for free and hear Rakesh discuss:
- Advances in maximizing TI of ADCs
- Next generation of cytotoxic warheads
- Advances in bispecific ADCs
- Translational approaches to ADC Development
Benefits to Downloading:
- Boost your knowledge about next generation antibody drug conjugates
- Learn more about the advances in maximizing TI of antibody drug conjugates
- Hear about the translational approaches to the development of antibody drug conjugates
Download for free here.
If you would like further information regarding this webinar, please contact Danielle Dalby today on +44 (0) 1865 248455 or email email@example.com